Skip to main content
HR 4829 109th Congress House Health Civil Rights and Liberties, Minority Issues Commerce Drug advertising Drug industry Drugs Fines (Penalties) Government Operations and Politics Government publicity Identification devices Intellectual property Labeling Law Packaging Product counterfeiting Right of privacy Science, Technology, Communications

Reducing Fraudulent and Imitation Drugs Act of 2006

Introduced: March 1, 2006 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 109th Congress ended
It never became law before the 109th Congress (2005–2006) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 17, 2006
Referred to the Subcommittee on Health.
Mar 1, 2006
Referred to the House Committee on Energy and Commerce.
Mar 1, 2006
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Reducing Fraudulent and Imitation Drugs Act of 2006 - Directs the Secretary of Health and Human Services to require prescription drug packaging to incorporate: (1) radio frequency tagging technology or similar trace and track technologies; (2) tamper-indicating technologies; and (3) blister security packaging when possible.

Directs the Secretary to: (1) require that such technologies be used exclusively to authenticate the pedigree of prescription drugs; and (2) prohibit such technologies from containing or transmitting any identifying information of a health care practitioner or consumer, or any advertisement or information about indications or off-label uses.

Requires the Secretary to encourage prescription drug manufacturers and distributors to incorporate: (1) overt optically variable counterfeit-resistant technologies into packaging; and (2) required prescription drug packaging technologies into multiple elements of the physical packaging of the drugs. Requires prescription drug shipments to include a label on the shipping container that incorporates packaging technologies.

Deems a prescription drug to be misbranded if the packaging or labeling of the drug is in violation of a requirement or prohibition of this Act.

Requires the Secretary to publish the National Specified List of Susceptible Prescription Drugs, consisting of not less than 30 of the most frequently counterfeited prescription drugs in the United States.

What's happening now March 17, 2006

Referred to the Subcommittee on Health.

 Related & companion bills 1
  • S 2668 Identical bill Reducing Fraudulent and Imitation Drugs Act of 2006
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 4
All 4 Democratic 1 Independent 1
WAMP, ZACH
· Jul 17, 2006
 D
DeLauro, Rosa L.
Connecticut · Jun 9, 2006
Herseth Sandlin, Stephanie
· Mar 1, 2006
 I
Sanders, Bernard
Vermont · Mar 1, 2006
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 4829: Reducing Fraudulent and Imitation Drugs Act of 2006. 109th Congress. Open America. https://openamerica.io/bill/109-HR-4829/
MLA
"H.R. 4829: Reducing Fraudulent and Imitation Drugs Act of 2006." 109th Congress, 2026, Open America, https://openamerica.io/bill/109-HR-4829/.
Bluebook (legal)
H.R. 4829, 109th Cong. (2026), https://openamerica.io/bill/109-HR-4829/.
Markdown link
[H.R. 4829: Reducing Fraudulent and Imitation Drugs Act of 2006](https://openamerica.io/bill/109-HR-4829/)
Report a problem